Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

674 Results

Guidelines and Advice

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Current
ID: GL-END 3-25

Nov 2023

Document

obsp-11-23-23.xml

Nov 2023

Document

obsp-11-23-23.html

Nov 2023

Document

obsp-12-04-23.xml

Dec 2023

Document

obsp-12-04-23.html

Dec 2023

Document

obsp-12-13-23.xml

Dec 2023

Document

obsp-12-12-23.xml

Dec 2023

Document

obsp-12-12-23a.xml

Dec 2023

Document

obsp-12-13-23.html

Dec 2023

Document

obsp-12-13-23a.xml

Dec 2023

Document

obsp-12-14-23.xml

Dec 2023

Document

obsp-12-14-23a.html

Dec 2023

Pages